Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Head & Neck 1Gastrointestinal 1Breast 1

Conditions

Colorectal Neoplasms 86Colonic Neoplasms 32Rectal Neoplasms 31Neoplasms 24Pancreatic Neoplasms 22Stomach Neoplasms 20Neoplasm Metastasis 20Esophageal Neoplasms 20Neuroblastoma 12Glioma 11Sarcoma 9Glioblastoma 9Small Cell Lung Carcinoma 8Carcinoma, Non-Small-Cell Lung 8Brain Neoplasms 8Adenocarcinoma Of Esophagus 8Rhabdomyosarcoma 7Lung Neoplasms 7Sarcoma, Ewing 6Gliosarcoma 6Esophageal Squamous Cell Carcinoma 6Medulloblastoma 5Central Nervous System Neoplasms 5Breast Neoplasms 5Parkinson Disease 4, Autosomal Dominant Lewy Body 4Intestinal Neoplasms 4Gastrointestinal Neoplasms 4Digestive System Neoplasms 4Digestive System Diseases 4Adenocarcinoma 4

Interventions

pembrolizumab 37Paclitaxel 36Carboplatin 31Cyclophosphamide 22Albumin-Bound Paclitaxel 20atezolizumab 16130-nm albumin-bound paclitaxel 16Taxes 15Doxorubicin 15Cisplatin 13Capecitabine 13Nivolumab 10Docetaxel 8olaparib 7Gemcitabine 6Everolimus 6talazoparib 5durvalumab 5Magnetic Resonance Spectroscopy 5Biopsy 5Bevacizumab 5veliparib 4spartalizumab 4sacituzumab govitecan 4pegfilgrastim 4liposomal doxorubicin 4eribulin 4Specimen Handling 4Immunoglobulin G 4trilaciclib 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Triple Negative Breast Neoplasms × Irinotecan × Clear all
NCT01451632 2016-09-08

A Safety Study of MM-121 With Cetuximab and Irinotecan in Patients With Advanced Cancers

Merrimack Pharmaceuticals

Phase 1 Completed
48 enrolled 14 charts
BreastGastrointestinalHead & NeckThoracic

Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡